User:Mr. Ibrahem/Atoltivimab/maftivimab/odesivimab

Atoltivimab/maftivimab/odesivimab, sold under the brand name Inmazeb, is a combination medication used to treat Ebola cause by the Zaire ebolavirus. Effectiveness for other Ebola viruses and Marburg is unclear. It is given by injection into a vein.

Common side effects include fever, fast heart rate, fast breathing, and vomiting; however, these are also common symptoms of Ebola virus infection. It is made up of three monoclonal antibodies; atoltivimab, maftivimab, and odesivimab that bind to a glycoprotein on Zaire ebolavirus.

The combination was approved for medical use in the United States in 2020. It is on the World Health Organization's List of Essential Medicines. As of 2022 it is not available in Europe or the United Kingdom. The United States government in 2020 bought doses for outbreak preparedness.